Atrion Co. (NASDAQ:ATRI) has received a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that provide coverage for the stock, Zacks Investment Research reports.

Zacks has also given Atrion an industry rank of 74 out of 255 based on the ratings given to related companies.

Several brokerages have recently issued reports on ATRI. BidaskClub upgraded Atrion from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 27th. ValuEngine upgraded Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th.

Hedge funds have recently modified their holdings of the stock. TIAA CREF Investment Management LLC raised its stake in shares of Atrion by 9.1% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 9,276 shares of the medical instruments supplier’s stock valued at $6,445,000 after acquiring an additional 776 shares in the last quarter. Virginia Retirement Systems ET AL bought a new position in shares of Atrion in the 4th quarter valued at approximately $889,000. Raymond James Financial Services Advisors Inc. raised its stake in shares of Atrion by 14.8% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 4,125 shares of the medical instruments supplier’s stock valued at $3,057,000 after acquiring an additional 531 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Atrion by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 84,115 shares of the medical instruments supplier’s stock valued at $58,443,000 after acquiring an additional 932 shares in the last quarter. Finally, Vanguard Group Inc raised its stake in shares of Atrion by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 84,115 shares of the medical instruments supplier’s stock valued at $58,443,000 after acquiring an additional 932 shares in the last quarter. 61.74% of the stock is currently owned by institutional investors and hedge funds.

Shares of Atrion stock opened at $920.05 on Monday. The stock has a market cap of $1.72 billion, a PE ratio of 50.41 and a beta of 0.44. Atrion has a 52-week low of $560.65 and a 52-week high of $948.03.

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were paid a $1.35 dividend. This represents a $5.40 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date was Thursday, March 14th.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Story: Backdoor Roth IRA

Get a free copy of the Zacks research report on Atrion (ATRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.